Page last updated: 2024-12-07

7-methyl-6,8-bis(methylthio)pyrrolo(1,2-a)pyrazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

7-methyl-6,8-bis(methylthio)pyrrolo(1,2-a)pyrazine: an oltipraz metabolite; also called metabolite III; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID128585
CHEMBL ID3799534
SCHEMBL ID6901008
MeSH IDM0249740

Synonyms (16)

Synonym
7-methyl-6,8-bis(methylthio)pyrrolo[1,2-a]pyrazine
6-methyl-5,7-dimethylthiopyrrolo[1,2-a]1,4-diazine
7-methyl-6,8-bis(methylsulfanyl)pyrrolo[1,2-a]pyrazine
metabolite iii
miii
mbmtpp
SCHEMBL6901008
7-methyl-6,8-bis(methylthio)pyrrolo(1,2-a)pyrazine
84201-40-1
pyrrolo(1,2-a)pyrazine, 7-methyl-6,8-bis(methylthio)-
DTXSID30233127
oltipraz metabolite m2
MYLBTCQBKAKUTJ-UHFFFAOYSA-N
7-methyl-6,8-bis(methylthio)pyrrolo[1,2]pyrazine
CHEMBL3799534
NCGC00480804-03

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" In the single-dose study, the area under the plasma concentration-time curve (AUC), peak plasma concentration (C(max)), and terminal half-life (t(1/2)) of oltipraz as well as the AUC of its RM were dose dependent."( Pharmacokinetics of oltipraz and its major metabolite (RM) in patients with liver fibrosis or cirrhosis: relationship with suppression of circulating TGF-beta1.
Cho, SH; Choi, JY; Choi, YH; Chon, CY; Han, JY; Jang, JJ; Jang, JW; Kim, SG; Kim, YM; Lee, DH; Lee, MG; Lee, YS; Um, SH; Yu, ES, 2010
)
0.36

Dosage Studied

ExcerptRelevanceReference
" Overall, the pharmacokinetics, safety, and efficacy of oltipraz suggest that it may be helpful in the treatment of patients with LF or LC, at an optimal dosing regimen."( Pharmacokinetics of oltipraz and its major metabolite (RM) in patients with liver fibrosis or cirrhosis: relationship with suppression of circulating TGF-beta1.
Cho, SH; Choi, JY; Choi, YH; Chon, CY; Han, JY; Jang, JJ; Jang, JW; Kim, SG; Kim, YM; Lee, DH; Lee, MG; Lee, YS; Um, SH; Yu, ES, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1299126Reduction of insulin-induced HIF-1 alpha target gene expression in human HCT116 cells assessed as decrease in Glut-1 expression at 10 uM by RT-PCR analysis2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Synthesis and biological evaluation of 1,2-dithiol-3-thiones and pyrrolo[1,2-a]pyrazines as novel hypoxia inducible factor-1 (HIF-1) inhibitor.
AID1299125Reduction of insulin-induced HIF-1 alpha target gene expression in human HCT116 cells assessed as decrease in VEGF expression at 10 uM by RT-PCR analysis2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Synthesis and biological evaluation of 1,2-dithiol-3-thiones and pyrrolo[1,2-a]pyrazines as novel hypoxia inducible factor-1 (HIF-1) inhibitor.
AID1299118Reduction of insulin-induced HIF-1 alpha expression in human HCT116 cells at 10 uM by western blot analysis2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Synthesis and biological evaluation of 1,2-dithiol-3-thiones and pyrrolo[1,2-a]pyrazines as novel hypoxia inducible factor-1 (HIF-1) inhibitor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's0 (0.00)29.6817
2010's4 (66.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.84 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (16.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]